Ventyx Biosciences, Inc. (NASDAQ:VTYX) Short Interest Update

Ventyx Biosciences, Inc. (NASDAQ:VTYX) was the target of a significant drop in short interest during the month of January. As of January 15th, there was short interest totaling 4,547,617 shares, a drop of 37.7% from the December 31st total of 7,294,699 shares. Based on an average daily volume of 9,715,154 shares, the days-to-cover ratio is presently 0.5 days. Currently, 7.8% of the shares of the stock are sold short. Currently, 7.8% of the shares of the stock are sold short. Based on an average daily volume of 9,715,154 shares, the days-to-cover ratio is presently 0.5 days.

Ventyx Biosciences Stock Performance

VTYX stock remained flat at $13.95 during midday trading on Friday. The company had a trading volume of 1,014,631 shares, compared to its average volume of 5,929,458. The firm has a 50-day simple moving average of $10.68 and a two-hundred day simple moving average of $6.51. Ventyx Biosciences has a one year low of $0.78 and a one year high of $25.00. The firm has a market cap of $995.46 million, a PE ratio of -9.30 and a beta of 1.23.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.13. As a group, research analysts forecast that Ventyx Biosciences will post -2.09 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Raju Mohan sold 47,345 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $365,503.40. Following the sale, the chief executive officer directly owned 2,372,863 shares in the company, valued at $18,318,502.36. The trade was a 1.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider John Nuss sold 12,675 shares of the stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $97,851.00. Following the completion of the transaction, the insider directly owned 489,481 shares of the company’s stock, valued at approximately $3,778,793.32. The trade was a 2.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 14.49% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC boosted its position in Ventyx Biosciences by 925.6% during the first quarter. AQR Capital Management LLC now owns 880,222 shares of the company’s stock worth $1,012,000 after purchasing an additional 794,401 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Ventyx Biosciences during the 1st quarter valued at approximately $56,000. Acadian Asset Management LLC grew its stake in Ventyx Biosciences by 443.8% in the 1st quarter. Acadian Asset Management LLC now owns 537,054 shares of the company’s stock valued at $614,000 after acquiring an additional 438,286 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in Ventyx Biosciences by 21.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 29,657 shares of the company’s stock worth $62,000 after acquiring an additional 5,174 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its position in Ventyx Biosciences by 104.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 46,711 shares of the company’s stock worth $100,000 after acquiring an additional 23,828 shares during the period. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Analyst Upgrades and Downgrades

VTYX has been the subject of several research reports. Piper Sandler cut Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 target price for the company. in a report on Thursday, January 8th. Canaccord Genuity Group downgraded shares of Ventyx Biosciences from a “buy” rating to a “hold” rating and dropped their price objective for the company from $16.00 to $14.00 in a research note on Thursday, January 8th. Wells Fargo & Company reissued an “equal weight” rating and issued a $14.00 price objective on shares of Ventyx Biosciences in a research note on Thursday, January 8th. Oppenheimer cut shares of Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a report on Thursday, January 8th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $14.00 price target (down from $20.00) on shares of Ventyx Biosciences in a report on Thursday, January 8th. Eight investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $14.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.